Lenalidomide in multiple myeloma: Current experimental and clinical data

European Journal of Haematology

Volumn 88, Issue 4, 2012, Pages 279-291

  Cives, Mauro ^a   Milano, Annalisa ^a   Dammacco, Franco ^a   Silvestris, Franco ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

Immunomodulatory drugs; Lenalidomide; Multiple myeloma; Osteoclastogenesis

Indexed keywords

BORTEZOMIB; CARFILZOMIB; CLARITHROMYCIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DACETUZUMAB; DEXAMETHASONE; DOXORUBICIN; ELOTUZUMAB; GRANULOCYTE COLONY STIMULATING FACTOR; I KAPPA B; LENALIDOMIDE; MELPHALAN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PLACEBO; PREDNISONE; THALIDOMIDE; VINCRISTINE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RELAPSE; CANCER SURVIVAL; CD34 SELECTION; CELL DEATH; CELL DIFFERENTIATION; CELL MEDIATED CYTOTOXICITY; CELL PROLIFERATION; DEEP VEIN THROMBOSIS; DNA METHYLATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; EPIGENETICS; FOLLOW UP; HERPES ZOSTER; HUMAN; HYPONATREMIA; IN VITRO STUDY; IN VIVO STUDY; LONG TERM CARE; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREMEDICATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT RESPONSE; UPREGULATION; VIRUS REACTIVATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNE SYSTEM; MEDICAL ONCOLOGY; MODELS, BIOLOGICAL; MULTIPLE MYELOMA; OSTEOCLASTS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 84858283875     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2011.01735.x     Document Type: Review

References (72)

1. Kotla V, Goel S, Nischal S, Heuck C, Vivek K, Das B, Verma A. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2009;2:36.
2. Teo S, Resztak K, Scheffler M, Kook KA, Zeldis JB, Stirling DI, Thomas SD. Thalidomide in the treatment of leprosy. Microbes Infect 2002;4:1193-202.
3. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002;100:3063-7.
4. Hayashi T, Hideshima T, Akiyama M, et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol 2005;128:192-203.
5. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000;96:2943-50.
6. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, Munshi NC, Treon SP, Anderson KC. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002;99:4524-30.
7. Lentzsch S, LeBlanc R, Podar K, Davies F, Lin B, Hideshima T, Catley L, Stirling DI, Anderson KC. Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo. Leukemia 2003;17:41-4.
8. Breitkreutz J, Raab MS, Vallet S, et al. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 2006;22:1925-32.
9. Silvestris F, Ciavarella S, De Matteo M, Tucci M, Dammacco F. Bone resorbing cells in multiple myeloma: osteoclasts, myeloma cell polycaryons or both? Oncologist 2009;14:264-75.
10. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350:1655-64.
11. Andersen TL, Boissy P, Sondergaard TE, Kupisiewicz K, Plesner T, Rasmussen T, Haaber J, Kølvraa S, Delaissè JM. Osteoclast nuclei of myeloma patients show chromosome translocations specific for the myeloma cell clone: a new type of cancer-host partnership? J Pathol 2007;211:10-7.
12. McDonald DF, Schofield BH, Prezioso EM, Adams VL, Frodonza CA, Trivedi SM, Craig C, Humphrey RL. Direct bone resorbing activity of murine myeloma cells. Cancer Lett 1983;19:119-24.
13. Van Der Pluijm G. Epithelial plasticity, cancer stem cells and bone metastasis formation. Bone 2011;48:37-43.
14. 3 integrin subunit mediates the bone-resorbing function exerted by cultured myeloma plasma cells. Cancer Res 2009;69:6738-46.
15. Zangari M, Tricot G, Zeldis J, Eddlemon P, Saghafifar F, Barlogie B. Results of phase I study of CC-5013 for the treatment of multiple myeloma (MM) patients who relapse after high dose chemotherapy (HDCT). Blood (ASH Annual Meeting Abstracts) 2001;98:775.
16. Richardson P, Jagannath S, Hussein M, et al. A multicenter, single-arm, open-label study to evaluate the efficacy and safety of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma; preliminary results. Blood (ASH Annual Meeting Abstracts) 2005;106:1565.
17. Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006;108:3458-64.
18. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus high-dose dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;22:357.
19. Weber DM, Chen C, Niesvizky R, Wang M, Belch A, Stadtmauer E, Yu Z, Olesnyckyj M, Zeldis J, Knight R. Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): results of a North American phase III study (MM-009), 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006;24(18 Suppl):7521.
20. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. New Engl J Med 2007;357:2123-32.
21. Armoiry X, Aulagner G, Facon T. Lenalidomide in the treatment of multiple myeloma: a review. J Clin Pharm Ther 2008;33:219-26.
22. Dimopoulos MA, Chen C, Spencer A, et al. Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia 2009;23:2147-52.
23. Harousseau JL, Dimopoulos MA, Wang M, et al. Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma. Haematologica 2010;95:1738-44.
24. San-Miguel JF, Dimopoulos MA, Stadtmauer EA, et al. Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Clin Lymphoma Myeloma Leuk 2011;11:38-43.
25. McCarthy P, Owzar K, Anderson K, et al. Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB ECOG BMT-CTN 100104. Haematologica 2011;96(S1):S23.
26. Attal M, Olivier P, Cances Lauwers V, et al. Maintenance treatment with lenalidomide after transplantation for myeloma: analysis of secondary malignancies within the IFM 2005-02 trial. Haematologica 2011;96(S1):S23.
27. Palumbo A, Delforge M, Catalano J, et al. A phase 3 study evaluating the efficacy and safety of lenalidomide combined with melphalan and prednisone in patients ≥65years with newly diagnosed multiple myeloma (NDMM): continuous use of lenalidomide vs fixed-duration regimens. Blood (ASH Annual Meeting Abstracts) 2010;116:622.
28. Palumbo A, Delforge M, Catalano J, Hajek R, Kropff M, Petrucci MT, Yu Z, Mei JM, Dimopoulos MA. Incidence of second primary malignancy (SPM) in melphalan-prednisone-lenalidomide combination followed by lenalidomide maintenance (MPR-R) in newly diagnosed multiple myeloma patients (pts) age 65 or older. J Clin Oncol 2011;29:8007.
29. Wang M, Dimopoulos MA, Chen C, et al. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapse or refractory multiple myeloma regardless of prior thalidomide exposure. Blood 2008;112:4445-51.
30. Knop S, Gerecke C, Liebisch P, et al. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood 2009;113:4137-43.
31. Baz R, Walker E, Karam MA, et al. Lenalidomide and pegylated liposomal -based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol 2006;17:1766-71.
32. Richardson PG, Weller E, Jagannath S, et al. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol 2009;27:5713-9.
33. Dimopoulos MA, Kastritis E, Christoulas D, et al. Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies. Leukemia 2010;24:1769-78.
34. San Miguel JF. Relapse/refractory myeloma patient: potential treatment guidelines. J Clin Oncol 2009;27:5676-7.
35. Palumbo A, Larocca A, Falco P, et al. Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma. Leukemia 2010;24:1037-42.
36. Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005;106:4050-3.
37. Zonder JA, Crowley J, Hussein MA, Bolejack V, Moore DF, Whittenberger BF, Abidi MH, Durie BGM, Barlogie B. Superiority of lenalidomide (len) plus high-dose dexamethasone (HD) compared to HD alone as treatment of newly-diagnosed multiple myeloma (NDMM): results of the randomized, double-blinded, placebo-controlled SWOG trial S0232. Blood 2007;110:77.
38. Kumar S, Dispenzieri A, Lacy MQ, et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007;21:2035-42.
39. Stewart KA, Richardson PG, San Miguel JF. How I treat multiple myeloma in younger patients. Blood 2009;114:5436-43.
40. Koh KR, Janz M, Mapara MY, Lemke B, Stirling D, Dörken B, Zenke M, Lentzsch S. Immunomodulatory derivative of thalidomide (IMiD CC-4047) induces a shift in lineage commitment by suppressing erythropoiesis and promoting myelopoiesis. Blood 2005;105:3833-40.
41. Kumar S, Giralt S, Stadtmauer EA, et al. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood 2009;114:1729-35.
42. Popat U, Saliba R, Thandi R, et al. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant 2009;15:718-23.
43. Cavallo F, Bringhen S, Milone G, et al. Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy. Leukemia 2011;25:1627-31.
44. Nazha A, Cook R, Vogl DT, et al. Stem cell collection in patients with multiple myeloma: impact of induction therapy and mobilization regimen. Bone Marrow Transplant 2011;46:59-63.
45. Micallef IN, Ho AD, Klein LM, Marulkar S, Gandhi PJ, McSweeney PA. Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide. Bone Marrow Transplant 2011;46:350-5.
46. Rajkumar SV, Jacobus S, Callander NS, Fonseca R, Vesole DH, Williams ME, Abonour R, Siegel DS, Katz M, Greipp PR. Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial. Lancet Oncol 2010;11:29-37.
47. Richardson PG, Weller E, Lonial S, et al. Lenalidomide, bortezomib and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010;116:679-86.
48. Palumbo A, Falco P, Corradini P, et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA-Italian Multiple Myeloma Network. J Clin Oncol 2007;25:4459-65.
49. Palumbo A, Falco P, Falcone A, et al. Melphalan, Prednisone, and Lenalidomide for newly diagnosed myeloma: kinetics of neutropenia and thrombocytopenia and time-to-event results. Clin Lymphoma Myeloma 2009;9:145-50.
50. Ohara T, Morishita T, Suzuki H, Masaoka T, Ishii H, Hibi T. Antibiotics directly induce apoptosis in B cell lymphoma cells derived from BALB/c mice. Anticancer Res 2004;24:3723-30.
51. Spahn JD, Fost DA, Covar R, Martin RJ, Brown EE, Szefler SJ, Leung DY. Clarithromycin potentiates glucocorticoid responsiveness in patients with asthma: results of a pilot study. Ann Allergy Asthma Immunol 2001;87:501-5.
52. Nakamura M, Kikukawa Y, Takeya M, Mitsuya H, Hata H. Clarithromycin attenuates autophagy in myeloma cells. Int J Oncol 2010;37:815-20.
53. Niesvizky R, Jayabalan DS, Christos PJ, et al. Biaxin® [clarithromycin]/Revlimid® [lenalidomide]/dexamethasone combination therapy results in high complete- and overall-response rates in treatment-naïve symptomatic multiple myeloma. Blood 2008;111:1101-9.
54. Palumbo A, Gay F, Falco P, et al. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. J Clin Oncol 2010;28:800-7.
55. Hasskarl J, Gabriele I, De Pasquale D, Schröttner P, Zerweck A, Wash R, Engelhardt M. Association of multiple myeloma with different neoplasms: systematic analysis in consecutive myeloma patients. Leuk Lymphoma 2011;52:247-59.
56. Mailankody S, Pfeiffer RM, Kristinsson SY, Korde N, Bjorkholm M, Goldin LR, Turesson I, Landgren O. Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). Blood 2011;118:4086-92.
57. Tueresson I, Velez R, Kristinsson SY, Landgren O. Patterns of improved survival in patients with multiple myeloma in the twenty-first century: a population-based study. J Clin Oncol 2009;28:830-4.
58. Kyle RA, Pierre RV, Bayrd ED. Multiple myeloma and acute myelomonocytic leukemia. N Engl J Med 1970;283:1121-5.
59. Cuzick J, Erskine S, Edelman D, Galton DA. A comparison of the incidence of the myelodysplastic syndrome and acute myeloid leukaemia following melphalan and cyclophosphamide treatment for myelomatosis. A report to the Medical Research Council's working party on leukaemia in adults. Br J Cancer 1987;55:523-9.
60. Govindarajan R, Jagannath S, Flick JT, Vesole DH, Sawyer J, Barlogie B, Tricot G. Preceding standard therapy is the likely cause of MDS after autotransplants for multiple myeloma. Br J Haematol 1996;95:349-53.
61. Landgren O, Polliack A, Tadmor T. Associations between multiple myeloma and other malignancies. Leuk Lymphoma 2011;52:161-2.
62. Escoubet-Lozach L, Lin IL, Jensen-Pergakes K, Brady HA, Gandhi AK, Schafer PH, Muller GW, Worland PJ, Chan KW, Verhelle D. Pomalidomide and lenalidomide induce p21 WAF-1 expression in both lymphoma and multiple myeloma through a LSD1-mediated epigenetic mechanism. Cancer Res 2009;69:7347-56.
63. Richardson PG, Weber DM, Mitsiades CS, Dimopoulos MA, Harousseau J, Howe J, Graef T, Byrne C, Anderson KC, Siegel DS. Phase I study of combined vorinostat (V), lenalidomide (L), and dexamethasone (D) in patients (pts) with relapsed or refractory multiple myeloma (MM). J Clin Oncol 2010;28(15 Suppl):8031.
64. Mateos M, Spencer A, Taylor K, Lonial S, De La Rubia J, Facon T, Bengoudifa B, Hazell K, Bourquelot M, San-Miguel JF. Phase Ib study of oral panobinostat (LBH589) plus lenalidomide (LEN) plus dexamethasone (DEX) in patients (Pts) with relapsed (Rel) or rel and refractory (Ref) multiple myeloma (MM). J Clin Oncol 2010;28(15 Suppl):8030.
65. Tai YT, Podar K, Mitsiades N, et al. CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling. Blood 2003;101:2762-9.
66. Agura E, Niesvizky R, Matous J, Munshi N, Hussein M, Parameswaran RV, Tarantolo S, Whiting NC, Drachman JG, Zonder JA. Dacetuzumab (SGN-40), lenalidomide, and weekly dexamethasone in relapsed or refractory multiple myeloma: multiple responses observed in a phase Ib study. Blood (ASH Annual Meeting Abstracts) 2009;114:2870.
67. Zonder JA, Singhal S, Bensinger W, Mohrbacher A, Hussein MA, Munshi NC, Caras I, Singhal A, van Rhee F. Phase I study of elotuzumab (HuLuc63) in relapsed/refractory multiple myeloma. Blood (ASH Annual Meeting Abstracts) 2008;112:2773.
68. Lonial S, Vij R, Facon T, et al. Phase I study of elotuzumab plus lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma. Haematologica 2011;96(S1):S103.
69. Richardson P, Moreau P, Jakubowiak A, et al. Phase 2 study of elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma. Haematologica 2011;96(S1):S106.
70. Vitale I, Galluzzi L, Castedo M, Kroemer G. Mitotic catastrophe: a mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol 2011;12:385-92.
71. Schey SA, Morgan GJ, Ramasamy K, Hazel B, Ladon D, Corderoy S, Jenner M, Phekoo K, Boyd K, Davies FE. The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed-refractory myeloma patients; a phase I/II study. Br J Haematol 2010;150:326-33.
72. Kumar S, Flinn IW, Noga SJ, et al. Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study. Leukemia 2010;24:1350-6.